The picture on this rare condition has been getting clearer ...

Data show many patients discontinue or switch treatment within the first year ...

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data ...

October 17, 2012 (Boston, Massachusetts) — The risk of the potentially life-threatening side effect angioedema differs between different classes of drugs that inhibit the renin-angiotensin-aldosterone ...

BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe — — ...

BioCryst granted an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize its navenibart drug for hereditary angioedema in Europe. BioCryst will receive $70 million upfront and be ...

New York, USA, May 06, 2025 (GLOBE NEWSWIRE) -- Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses ...

Angioedema is a well-known side effect of treatment with an angiotensin-converting enzyme (ACE) inhibitor and one that we have been willing to accept in view of the incidence of the problem and the ...

The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma ...

Hereditary angioedema (HAE) is a rare genetic syndrome caused by a deficiency in functional C1 inhibitor that results in recurrent episodes of nonpruritic swelling of the hands, feet, arms, legs, ...